Courtesy: The New York Times
Judging by some of the heavy action in the world of biotechnology, one could easily conclude that the industry is going to the dogs. Or cats, maybe.
There are start-ups named Nexvet and VetDC, CanFel Therapeutics (as in canine and feline), and even Fetch Pharma.
It’s a new example of pack behavior: Entrepreneurs with pedigrees from companies like Genentech and Amgen are now turning their attention to pets. They hope to develop innovative drugs for dogs and cats like those that have revolutionized the treatment of diseases like cancer and arthritis in people.